GUILFORD, Conn.--(BUSINESS WIRE)--Swoop® portable MRI system receives CDSCO approval in India, expanding access to advanced brain imaging in a large, fast-growing healthcare market.

Hyperfine, Inc. (NASDAQ: HYPR - Get Free Report) dropped 6.8% during mid-day trading on Monday. The stock traded as low as $0.9250 and last traded at $0.9277. Approximately 3,219,550 shares changed hands during trading, an increase of 501% from the average daily volume of 536,113 shares. The stock had previously closed at $0.9959. Analyst Ratings

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine secures FDA clearance for new DWI sequence, significantly expanding the Swoop® system's clinical capabilities in acute neurological care.

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine announces plans to present at the upcoming Piper Sandler 37th Annual Healthcare Conference on Thursday, December 4th at 8:10 AM ET.

GUILFORD, Conn.--(BUSINESS WIRE)--$3.7M grant supports expanded use of portable MRI to evaluate brain development and guide targeted health interventions in underserved communities.

Hyperfine (NASDAQ: HYPR - Get Free Report) and Vasamed (OTCMKTS:VSMD - Get Free Report) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability and risk. Analyst Ratings This is a breakdown of recent recommendations for

Hyperfine, Inc. ( HYPR ) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Webb Campbell Maria Sainz - CEO, President & Director Brett Hale - Chief Administrative Officer, CFO, Chief Compliance Officer, Treasurer & Corporate Secretary Conference Call Participants Frank Takkinen - Lake Street Capital Markets, LLC, Research Division Yuan Zhi - B. Riley Securities, Inc., Research Division Presentation Operator Good afternoon, and welcome to Hyperfine's Third Quarter 2025 Earnings Conference Call.

Hyperfine, Inc. (HYPR) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.14 per share a year ago.

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine today announced third quarter 2025 financial results and provided a business update.

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine launches study to assess Swoop® System use in neurosurgical ORs, advancing accessible brain MRI across care settings.